We have congregated information in relation to stocks with the highest payout ratio up until now. The payout ratio in itself isn't a assurance of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know and anything around 60 percent is considered high.
1. Novartis
99.91% Payout Ratio
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.
As maintained by Morningstar, Inc., the next dividend payment is on Mar 2, 2020, the estimated forward annual dividend rate is 3.09 and the estimated forward annual dividend yield is 3.4%.
News about Novartis today
Sosei heptares and GSK enter global collaboration and license agreement targeting immune disorders of the digestive system. According to today's article on Business Insider, "We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. "
Novartis gets CRL from FDA due to unresolved facility inspection-related conditions on inclisiran. According to today's article on Business Insider, "Novartis said it will work with the FDA and the third-party manufacturing facility in Europe to complete the inclisiran review, to bring this potential first-in-class siRNA to patients in the U.S. as quickly as possible.", "According to Novartis, the FDA stated that the agency cannot approve the NDA by the Prescription Drug User Fee Act (PDUFA) action date of December 23, 2020, due to unresolved facility inspection-related conditions. "
Novartis's sales growth this year is expected to be 3.6% and 6.2% for next year.
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 49.58B for the twelve trailing months.
Novartis's sales growth is 3.9% for the current ongoing quarter and 6.3% for the next. The company's growth estimates for the current quarter and the next is 2.3% and 1.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.25%.
Novartis's Stock Yearly Top and Bottom Value
Novartis's stock is valued at $90.91 at 07:23 EST, under its 52-week high of $99.84 and way higher than its 52-week low of $69.18.
Novartis's Moving Average
Novartis's value is higher than its 50-day moving average of $88.10 and above its 200-day moving average of $86.86.Previous days news about Novartis
Novartis : FDA panel recommends entresto to treat patients with hfpef. According to Business Insider on Wed Dec 16, "Novartis (NVS) said Tuesday that the US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction or HfpEF."
Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Novartis (NVS) - Novartis received a Food and Drug Administration panel endorsement to expand use of its heart failure drug Entresto, currently approved for patients whose heart muscles do not contract effectively. ", "Novartis shares were up 1% in the premarket."
Novartis to buy cadent therapeutics for up to $770 million. According to Bloomberg Quint on Thu Dec 17, "Novartis will pay $210 million up front and privately owned Cadent will be eligible for payments of as much as $560 million upon meeting certain milestones, the Cambridge, Massachusetts-based company said Thursday.", "Cadent is developing a drug for schizophrenia, and it has an alliance already with Novartis on a product for treatment-resistant depression."
Vaccines don’t mean we’ll see the last of covid, experts warn. According to Bloomberg Quint on Sun Dec 20, "The world is likely to see the same level of viral persistence from the coronavirus, said Klaus Stohr, a former Novartis AG vaccine executive and WHO official who championed efforts to prepare for pandemics."
2. VALE S.A.
137.51% Payout Ratio
Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally.
According to Morningstar, Inc., the next dividend payment is on Sep 21, 2020, the estimated forward annual dividend rate is 0.69 and the estimated forward annual dividend yield is 4.08%.
VALE S.A. 's sales growth this year is anticipated to be negative 0.2% and 9.5% for next year.
Year-on-year quarterly revenue growth grew by 42.4%, now sitting on N/A for the twelve trailing months.
VALE S.A. 's sales growth is 20.9% for the present present quarter and 39.8% for the next. The company's growth estimates for the present quarter and the next is 691.7% and 728.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.79%.
VALE S.A. 's Stock Yearly Top and Bottom Value
VALE S.A. 's stock is valued at $16.86 at 07:23 EST, under its 52-week high of $17.05 and way above its 52-week low of $6.49.
VALE S.A. 's Moving Average
VALE S.A. 's worth is way higher than its 50-day moving average of $13.07 and way higher than its 200-day moving average of $11.51.3. Taubman Centers, Inc.
45.68% Payout Ratio
Taubman Centers is an S&P MidCap 400 Real Estate Investment Trust engaged in the ownership, management and/or leasing of 26 regional, super-regional and outlet shopping centers in the U.S. and Asia.
Taubman Centers, Inc.'s sales growth this year is anticipated to be negative 19.6% and 4.6% for next year.
Year-on-year quarterly revenue growth declined by 19.4%, now sitting on 585.73M for the twelve trailing months.
Taubman Centers, Inc.'s sales growth is negative 21.1% for the ongoing quarter and negative 16.2% for the next. The company's growth estimates for the current quarter and the next is negative 133.3% and negative -128.1%.
Taubman Centers, Inc.'s Stock Yearly Top and Bottom Value
Taubman Centers, Inc.'s stock is valued at $42.91 at 07:23 EST, way below its 52-week high of $53.40 and way above its 52-week low of $26.24.
Taubman Centers, Inc.'s Moving Average
Taubman Centers, Inc.'s value is way higher than its 50-day moving average of $38.90 and way higher than its 200-day moving average of $37.88.4. Public Service Enterprise Group Incorporated
51.46% Payout Ratio
Public Service Enterprise Group Incorporated, through its subsidiaries, operates as an energy company primarily in the Northeastern and Mid-Atlantic United States.
As maintained by Morningstar, Inc., the next dividend payment is on Dec 8, 2020, the estimated forward annual dividend rate is 1.96 and the estimated forward annual dividend yield is 3.45%.
Public Service Enterprise Group Incorporated's sales growth this year is expected to be negative 1.6% and 4.6% for next year.
Year-on-year quarterly revenue growth grew by 3%, now sitting on 9.68B for the twelve trailing months.
Public Service Enterprise Group Incorporated's sales growth is 15.3% for the ongoing present quarter and 20.8% for the next. The company's growth estimates for the current quarter and the next is negative 3.1% and 2.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.43%.
Public Service Enterprise Group Incorporated's Stock Yearly Top and Bottom Value
Public Service Enterprise Group Incorporated's stock is valued at $56.82 at 07:23 EST, under its 52-week high of $62.15 and way above its 52-week low of $34.75.